Back to search results
NCT06269705

ZILRETTA in Subjects With Shoulder Osteoarthritis

Active, Not Recruiting
PHASE3Ages 50–80InterventionalTreatment
Pacira Pharmaceuticals, Inc
~150 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:ZILRETTAPlacebo

At a glance

Recruiting sites
0 of 32 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 12 for ZILRETTA relative to placebo
Measured over Week 12

Conditions

Glenohumeral Osteoarthritis

Explore related trials

Osteoarthritis of glenohumeral joint

NCT06269705

Where you'd take part

This study runs at 32 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Alabama Orthopaedic Center- Research

    Vestavia Hills, Alabamano site contact published

  • Altoona Arthritis & Osteoporosis Center - Altoona Center for Clinical Research

    Duncansville, Pennsylvaniano site contact published

  • Baptist Health Orthopedic Care - Miami Gardens

    Maimi, Floridano site contact published

  • Clinical Research of West Florida

    Tampa, Floridano site contact published

  • El Paso Clinical Trials, LLC

    El Paso, Texasno site contact published

  • First Surgical Hospital

    Bellaire, Texasno site contact published

  • Gulfcoast Research Institute

    Sarasota, Floridano site contact published

  • Horizon Clinical Research

    La Mesa, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nino Joy, MD · STUDY_DIRECTOR · Pacira Pharmaceuticals, Inc

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 12 for ZILRETTA relative to placeboWeek 12